Sartorius Stedim Biotech S.A. (FRA:56S1)

Market Cap	18.32B -8.5%
Revenue (ttm)	2.95B +7.7%
Net Income	263.90M +64.3%
EPS	2.71 +61.1%
Shares Out	n/a
PE Ratio	69.43
Forward PE	35.55
Dividend	0.69 (0.33%)
Ex-Dividend Date	Apr 2, 2025

Volume	n/a
Average Volume	42
Open	209.10
Previous Close	205.70
Day's Range	209.10 - 209.10
52-Week Range	154.60 - 235.20
Beta	n/a
RSI	34.18
Earnings Date	Feb 3, 2026

About Sartorius Stedim Biotech

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiolog...

• Industry: Laboratory Analytical Instruments
• Founded: 1978
• Employees: 10,134
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 56S1

Financial Performance

In 2024, Sartorius Stedim Biotech's revenue was 2.78 billion, an increase of 0.16% compared to the previous year's 2.78 billion. Earnings were 175.10 million, a decrease of -43.57%.